Eli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday
Eli Lilly and Company (NYSE:LLY) is set to issue its quarterly earnings data before the market opens on Tuesday, October 24th. Analysts expect the company to announce earnings of $1.03 per share for the quarter. Eli Lilly and has set its FY17 guidance at $4.10-4.20 EPS.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.86 EPS. On average, analysts expect Eli Lilly and to post $4.16 EPS for the current fiscal year and $4.60 EPS for the next fiscal year.
Shares of Eli Lilly and Company (NYSE LLY) opened at 85.95 on Tuesday. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The firm’s 50-day moving average price is $83.56 and its 200 day moving average price is $82.19. The stock has a market capitalization of $90.68 billion, a P/E ratio of 37.19 and a beta of 0.34.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.42%. Eli Lilly and’s payout ratio is currently 90.04%.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 990,000 shares of company stock valued at $82,949,650. 0.20% of the stock is owned by company insiders.
LLY has been the topic of a number of recent analyst reports. UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 price target on the stock. in a report on Wednesday, July 26th. BMO Capital Markets reaffirmed a “sell” rating and set a $71.00 price target on shares of Eli Lilly and in a report on Thursday, September 28th. Jefferies Group LLC reaffirmed a “buy” rating and set a $93.00 price target on shares of Eli Lilly and in a report on Thursday, June 22nd. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the company a “hold” rating in a report on Friday, October 6th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a report on Friday. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $88.97.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.